Drug Trial Radar · NCT04516447
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
172
Planned (sponsor's estimate)
Start
Oct 26, 2020
Primary completion
Jun 30, 2028
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 18, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.
Conditions
- Solid Tumor
- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer
Interventions
AzenosertibDrug
Investigational drug
CarboplatinDrug
Carboplatin is an approved drug
Pegylated liposomal doxorubicinDrug
Pegylated liposomal doxorubicin (PLD) is an approved drug
PaclitaxelDrug
Paclitaxel is an approved drug
GemcitabineDrug
Gemcitabine is an approved drug
BevacizumabBiological
Bevacizumab is an approved drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: To investigate the safety and tolerability of azenosertib in combination with PLD, carboplatin, paclitaxel, or gemcitabineTime frame: Through study completion, an average of 1 year
- Part 1: To identify the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of azenosertib in combination with PLD, carboplatin, paclitaxel, or gemcitabineTime frame: Through Cycle 1 (cycle is 28 days for PLD or paclitaxel, and 21 days for carboplatin, or gemcitabine)
- Part 2: To estimate the safety/tolerability of azenosertib in combination with bevacizumabTime frame: Through study completion, an average of 1 year
- Part 2: To identify the recommended dose for Part 2 Dose ExpansionTime frame: Through Cycle 1 (21 days)
Locations
35 sites in 8 countries. Site status is shown where the registry gives one.
Site 0264
Aurora, Colorado · Active not recruiting
Site 0104
Boston, Massachusetts · Recruiting
Site 0111
St Louis, Missouri · Recruiting
Site 0173
New York, New York · Recruiting
Site 0259
Durham, North Carolina · Recruiting
Site 0191
Providence, Rhode Island · Recruiting
Site 0196
Nashville, Tennessee · Completed
Site 0103
Houston, Texas · Recruiting
Site 2707
South Brisbane, Queensland, Australia · Completed
Site 2708
Sunshine Coast, Queensland, Australia · Completed
Site 2718
Sunshine Coast, Queensland, Australia · Recruiting
Site 2709
Adelaide, South Australia, Australia · Completed
Site 2716
Melbourne, Victoria, Australia · Recruiting
Site 2706
Melbourne, Victoria, Australia · Completed
Site 2705
Nedlands, Western Australia, Australia · Completed
Site 1001
Banja Luka, Bosnia and Herzegovina · Completed
Site 1002
Sarajevo, Bosnia and Herzegovina · Completed
Site 1003
Tuzla, Bosnia and Herzegovina · Completed
Site 1202
Panagyurishte, Bulgaria · Completed
Site 1201
Sofia, Bulgaria · Completed
3613
Besançon, France · Not yet recruiting
3624
Bordeaux, France · Recruiting
3601
Dijon, France · Recruiting
3608
Lyon, France · Not yet recruiting
3614
Nantes, France · Not yet recruiting
3623
Paris, France · Not yet recruiting
3604
Paris, France · Not yet recruiting
3625
Rennes, France · Recruiting
3611
Strasbourg, France · Not yet recruiting
3603
Toulouse, France · Recruiting
Site 1401
Tbilisi, Georgia · Completed
Site 1902
Belgrade, Serbia · Completed
Site 2901
Busan, South Korea · Completed
Site 2903
Seoul, South Korea · Completed
Site 2904
Seoul, South Korea · Completed
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.